Please login to the form below

Not currently logged in
Email:
Password:

Nexavar

This page shows the latest Nexavar news and features for those working in and with pharma, biotech and healthcare.

Roche files Tecentriq/Avastin combo in liver cancer

Roche files Tecentriq/Avastin combo in liver cancer

Patients received PD-L1 inhibitor Tecentriq plus anti-VEGF antibody Avastin or Bayer’s Nexavar (sorafenib) – a standard first-line therapy for HCC.

Latest news

More from news
Approximately 8 fully matching, plus 84 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    The recent upholding of the Indian patent office's rejection of Novartis' Glivec patent application is the latest in a series of actions including the compulsory licence of Nexavar and initiation

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    In its phase 3 trial it was compared with a single rival targeted therapy, Nexavar (sorafenib). ... A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....